Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy (MoveDMD®)

Catabasis Pharmaceuticals

Status and phase: Completed; Phase 2; Phase 1

Conditions: Muscular Dystrophy, Duchenne

Treatments: Drug: Edasalonexent; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02439216

CAT-1004-201

Details and patient eligibility

About

The MoveDMD study is a 3-part, Phase 1/2, multi-site study to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of edasalonexent (also known as CAT-1004) in pediatric patients with a genetically confirmed diagnosis of DMD. Male patients from ≥4 to <8 years of age will be enrolled.

Edasalonexent is an orally administered small molecule targeted to inhibit activated NF-κB, a molecule that is activated from infancy in DMD and which is central to causing muscle damage and preventing muscle regeneration. Data on magnetic resonance imaging of the lower and upper leg muscles, physical function (including timed function tests) and muscle strength will be studied.

Full description

Part A was a 1-week, open-label study to assess safety, tolerability, pharmacokinetics and biomarkers for three dose levels of edasalonexent and is now complete.

Part B was a randomized, double-blind, placebo-controlled, multiple dose study to evaluate the safety, efficacy, PK, and PD of edasalonexent over 12 weeks. Patients who participated in Part A also participated in Part B, along with newly enrolled patients. Patients received either edasalonexent 67 mg/kg/day, edasalonexent 100 mg/kg/day, or placebo in Part B. Part B is now complete.

Following completion of Part B, patients receive edasalonexent for 138 weeks in Part C, the open-label portion of the MoveDMD study. Patients on the 67 mg/kg/day treatment moved to the 100 mg/kg/day treatment. Patients on the 100 mg/kg/day treatment remained on the 100 mg/kg/day treatment. If clinically indicated, concomitant treatment with eteplirsen (Exondys 51™) may be acceptable in patients with amenable gene mutations during Part C after the patient has been exposed to edasalonexent for 6 months.

**Following completion of MoveDMD Part C, access to edasalonexent for trial participants will continue through the open-label extension study, GalaxyDMD.**

Enrollment: 31 patients

Sex: Male

Ages: 4 to 7 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent from parent or legal guardian prior to participation and, for patients who are 7 years of age, written assent from patient
• Diagnosis of DMD based on a clinical phenotype with increased serum CK and the presence of a mutation in the dystrophin gene known to be associated with a DMD phenotype
• Ability to walk independently (assistive devices are permitted)
• Adequate immunization for influenza and varicella

Exclusion criteria

• Use of corticosteroids within prior 6 months of treatment initiation or planning to initiate steroid therapy within the next 6 months

• Other prior or ongoing significant medical conditions

• Exposure to another investigational drug (such as eteplirsen or idebenone) within 28 days prior to start of study treatment or ongoing participation in any other therapeutic clinical trial

  • Note: There are separate criteria for patients who participated in Part A versus newly enrolling patients. New patients must meet all of the Part A entry criteria to participate in Part B.

Patients who participated in Part A must meet the following criteria to participate in Part B:

• Completed Part A
• Continue to meet all of the Part A entry criteria, including an absence of safety concerns (however, patients may be ≥8 years of age)

There are no entry criteria for Part C; all patients who complete Part B will automatically continue in Part C

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

31 participants in 3 patient groups, including a placebo group

Dose 1

Experimental group

Description:

Edasalonexent 67 mg/kg/day. Capsules taken by mouth two times per day

Treatment:

Drug: Edasalonexent

Dose 2

Experimental group

Description:

Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day

Treatment:

Drug: Edasalonexent

Placebo

Placebo Comparator group

Description:

Matching placebo

Treatment:

Drug: Placebo